Clinical Trial Update: Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating nicorandil, targeting ABCC9 pathways, for hippocampal sclerosis of aging with dementia and mild cognitive impairment. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Dementia
• Hippocampal Sclerosis of Aging

Drugs mentioned

• Nicorandil (nicorandil)

Snippet

Sponsor: Gregory Jicha, MD, PhD | Conditions: Dementia, Mild Cognitive Impairment | Phase 2 | Status: ACTIVE_NOT_RECRUITING